Systemic therapy in men with metastatic castration-resistant prostate cancer: American society of clinical oncology and cancer care ontario clinical practice guideline

Keyphrases

• Clinical Practice Guidelines 100%
• Prednisone 100%
• American Society of Clinical Oncology 100%
• Systemic Therapy 100%
• Metastatic Castration-resistant Prostate Cancer (mCRPC) 100%
• Oncology Care 100%
• Toxicity Risk 100%
• Cancer Care Ontario 100%
• Clinical Cancer 100%
• Docetaxel 83%
• Improved Survival 66%
• Quality of Life 33%
• Clinical Benefit 33%
• Bevacizumab 33%
• Mitoxantrone 33%
• Quality of Life Impact 33%
• Sunitinib 33%
• High Toxicity 33%
• Cabazitaxel 33%
• Enzalutamide 33%
• Sipuleucel-T 33%
• Estramustine 33%
• Abiraterone Acetate 33%
• Minimally Symptomatic 33%
• 223Ra 33%
• Evidence-based Recommendations 16%
• Risk-benefit 16%
• Treatment Recommendations 16%
• Flutamide 16%
• Antiandrogen 16%
• Palliative Care 16%
• Clinical Toxicity 16%
• Systematic Literature Review 16%
• Expert Panel 16%
• Optimal Combination 16%
• Survival Benefit 16%
• Low Toxicity 16%
• Ketoconazole 16%
• Quality of Life Improvement 16%
• Bone Metastasis 16%
• Androgen Deprivation Therapy 16%
• Radium-223 16%
• Optimal Sequence 16%
• Combination of Therapies 16%
• Sequence of Therapy 16%
• Bicalutamide 16%
• Nilutamide 16%
• Excess Toxicity 16%
• Lack of Evidence 16%
• Androgen Deprivation 16%
• Benefit-risk Balance 16%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Systemic Therapy 100%
• Prednisone 100%
• Clinical Oncology 100%
• Castration Resistant Prostate Cancer 100%
• Quality of Life 83%
• Docetaxel 83%
• Bevacizumab 33%
• Sunitinib 33%
• Mitoxantrone 33%
• Abiraterone Acetate 33%
• Estramustine 33%
• Enzalutamide 33%
• Sipuleucel T 33%
• Cabazitaxel 33%
• Symptomatic Treatment 16%
• Androgen 16%
• Antiandrogen 16%
• Systematic Review 16%
• Ketoconazole 16%
• Bone Metastasis 16%
• Androgen Deprivation Therapy 16%
• Flutamide 16%
• Bicalutamide 16%
• Nilutamide 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Malignant Neoplasm 100%
• Prednisone 100%
• Castration Resistant Prostate Cancer 100%
• Docetaxel 83%
• Bevacizumab 33%
• Androgen 33%
• Mitoxantrone 33%
• Sunitinib 33%
• Cabazitaxel 33%
• Sipuleucel T 33%
• Enzalutamide 33%
• Estramustine 33%
• Abiraterone Acetate 33%
• Flutamide 16%
• Antiandrogen 16%
• Ketoconazole 16%
• Bone Metastasis 16%
• Bicalutamide 16%
• Nilutamide 16%